ISTH/X
Jun 11, 2025, 07:38
At ISTH 2025, Novo Nordisk Will Share Phase 3 Hemophilia Study Results
Novo Nordisk US shared on X:
“Novo Nordisk is presenting our latest hemophilia research data, including key phase 3 studies, at ISTH2025.”
Stay informed with Hemostasis Today.
-
Feb 26, 2026, 15:24Nancy Shapiro: Excited to See This Publication on Current Landscape of Anticoagulation Stewardship Released
-
Feb 26, 2026, 15:15Ahmed Nasreldein: Stay Current on Key Updates in Ischemic and Hemorrhagic Stroke
-
Feb 26, 2026, 15:15Shannon Farmer: What Happens to Vital Signs Pre and Post 1-Unit and 2-Unit RBC Transfusion?
-
Feb 26, 2026, 15:08Emmanuel J Favaloro: When Is A ‘Subtype’ of VWD Not Really VWD?
-
Feb 26, 2026, 15:03Gregory Piazza: Importance of Recognizing PE As A Wide Spectrum of Presentations and Greater Range of Adverse Outcomes
-
Feb 26, 2026, 14:57Abdulla A. Damluji: Sex As An Effect Measure Modifier Between Frailty and Outcomes in AMI Patients
-
Feb 26, 2026, 14:48Ney Carter Borges: The APERITIF Trial Clarifies Rivaroxaban’s Role in LVT
-
Feb 26, 2026, 14:44Wolfgang Miesbach: Synovitis and Haemophilia in Focus at GTH2026
-
Feb 26, 2026, 14:40Al-Ola Abdallah: How Much Does It Cost to Publish in Hematology and Oncology Journals